Ruba Sarsour, DO
Nephrology · Scottsbluff, NENPI 1558628743
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $252 of the $372 with a category attached, or 67.7%. 6 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 26.9% of the total. 2025 is the largest year on record at $113, 7.9 times the $14 reported in 2019. That places this record below the midpoint for nephrology clinicians in NE, where the typical reported total is $1,214.
Across 15 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$100
- Otsuka America Pharmaceutical, Inc.$97
- Scpharmaceuticals Inc.$63
- Travere Therapeutics, Inc.$58
- Amgen$42
- Bayer$11
What the payments were for
- Food & beverage$25268%
- Education$12032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| Scpharmaceuticals Inc. | 1 | $63 |
| Travere Therapeutics, Inc. | 4 | $58 |
| Amgen | 3 | $42 |
| Bayer | 1 | $11 |
How this compares
$372 in reported general payments places this provider in the 25th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 51 | $11,880 |
| Calcium Acetate | 25 | $3,271 |
| Midodrine Hcl | 33 | $2,106 |
| Bumetanide | 46 | $1,420 |
| Losartan Potassium | 63 | $617 |
| Carvedilol | 89 | $505 |
| Amlodipine Besylate | 60 | $489 |
| Pantoprazole Sodium | 26 | $424 |
| Hydralazine Hcl | 45 | $385 |
| Tamsulosin Hcl | 15 | $382 |
| Allopurinol | 48 | $326 |
| Clonidine Hcl | 32 | $313 |
| Furosemide | 58 | $311 |
| Minoxidil | 11 | $304 |
| Calcitriol | 12 | $223 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Scottsbluff
- Kristine SoltanpourScottsbluff$3K
- Eric WiebeScottsbluff$968
- Michael AaronsonLincoln$498K
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Rachel BrockLincoln$87K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.